Charles Pitman CFA
Stock Analyst at Barclays
(4.74)
# 671
Out of 5,004 analysts
227
Total ratings
70.2%
Success rate
16%
Average return
Main Sectors:
Stocks Rated by Charles Pitman CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SWX: LONN Lonza Group AG | Reiterated: Buy | CHF 730.00 | CHF 569.20 | +28.25% | 33 | Sep 24, 2026 | |
| EPA: IPN Ipsen S.A. | Reiterated: Sell | €155.00 | €143.30 | +8.16% | 33 | Sep 21, 2026 | |
| SWX: BANB Bachem Holding AG | Reiterated: Hold | CHF 70.00 → CHF 80.00 | CHF 81.30 | -1.60% | 13 | Sep 8, 2026 | |
| SWX: PPGN PolyPeptide Group AG | Reiterated: Hold | CHF 44.31 | CHF 44.10 | +0.48% | 8 | Sep 8, 2026 | |
| ETR: BAYN Bayer Aktiengesellschaft | Reiterated: Buy | €60.00 → €70.00 | €50.02 | +39.94% | 18 | Sep 8, 2026 | |
| ETR: MRK Merck KGaA | Reiterated: Hold | €140.00 → €150.00 | €135.00 | +11.11% | 22 | Sep 8, 2026 | |
| EPA: DIM Sartorius Stedim Biotech S.A. | Reiterated: Buy | €210.00 → €240.00 | €212.40 | +12.99% | 19 | Sep 8, 2026 | |
| EPA: BIM bioMérieux S.A. | Reiterated: Hold | €75.00 → €80.00 | €77.70 | +2.96% | 8 | Sep 7, 2026 | |
| BIT: DIA DiaSorin S.p.A. | Reiterated: Sell | €60.00 → €70.00 | €78.80 | -11.17% | 4 | Sep 7, 2026 | |
| BIT: REC Recordati Industria Chimica e Farmaceutica S.p.A. | Reiterated: Hold | €48.00 → €50.00 | €53.05 | -5.75% | 16 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €270.00 | €258.30 | +4.53% | 22 | Apr 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €13.50 → €12.50 | €9.59 | +30.29% | 17 | Apr 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | CHF 75.00 | CHF 71.16 | +5.40% | 1 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $14.32 | - | 1 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $574.00 | - | 1 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $666 → $746 | $959.49 | n/a | 9 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $20 | $7.34 | n/a | 1 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $264.34 | n/a | 1 | Jan 13, 2022 |
Lonza Group AG
Sep 24, 2026
Reiterated: Buy
Price Target: CHF 730.00
Current: CHF 569.20
Upside: +28.25%
Ipsen S.A.
Sep 21, 2026
Reiterated: Sell
Price Target: €155.00
Current: €143.30
Upside: +8.16%
Bachem Holding AG
Sep 8, 2026
Reiterated: Hold
Price Target: CHF 70.00 → CHF 80.00
Current: CHF 81.30
Upside: -1.60%
PolyPeptide Group AG
Sep 8, 2026
Reiterated: Hold
Price Target: CHF 44.31
Current: CHF 44.10
Upside: +0.48%
Bayer Aktiengesellschaft
Sep 8, 2026
Reiterated: Buy
Price Target: €60.00 → €70.00
Current: €50.02
Upside: +39.94%
Merck KGaA
Sep 8, 2026
Reiterated: Hold
Price Target: €140.00 → €150.00
Current: €135.00
Upside: +11.11%
Sartorius Stedim Biotech S.A.
Sep 8, 2026
Reiterated: Buy
Price Target: €210.00 → €240.00
Current: €212.40
Upside: +12.99%
bioMérieux S.A.
Sep 7, 2026
Reiterated: Hold
Price Target: €75.00 → €80.00
Current: €77.70
Upside: +2.96%
DiaSorin S.p.A.
Sep 7, 2026
Reiterated: Sell
Price Target: €60.00 → €70.00
Current: €78.80
Upside: -11.17%
Recordati Industria Chimica e Farmaceutica S.p.A.
Jul 30, 2026
Reiterated: Hold
Price Target: €48.00 → €50.00
Current: €53.05
Upside: -5.75%
Apr 23, 2026
Reiterated: Buy
Price Target: €270.00
Current: €258.30
Upside: +4.53%
Apr 22, 2026
Reiterated: Buy
Price Target: €13.50 → €12.50
Current: €9.59
Upside: +30.29%
Mar 11, 2026
Reiterated: Hold
Price Target: CHF 75.00
Current: CHF 71.16
Upside: +5.40%
Jan 6, 2026
Upgraded: Buy
Price Target: n/a
Current: $14.32
Upside: -
Jan 6, 2026
Downgraded: Sell
Price Target: n/a
Current: $574.00
Upside: -
Apr 28, 2025
Reiterated: Buy
Price Target: $666 → $746
Current: $959.49
Upside: n/a
Jan 4, 2024
Upgraded: Buy
Price Target: $20
Current: $7.34
Upside: n/a
Jan 13, 2022
Initiated Coverage: Buy
Price Target: n/a
Current: $264.34
Upside: n/a